Treatment-emergent behavioural side effects with selective serotonin re-uptake inhibitors in adults with learning disabilities

Human Psychopharmacology

Volumn 16, Issue 2, 2001, Pages 133-137

  Biswas, A B ^a,c   Bhaumik, S ^a   Branford, D ^b  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b KINGSWAY HOSPITAL   (United Kingdom)

^c Leicester Frith Hospital   (United Kingdom)

Author keywords

Depression; Fluoxetine; Learning disabilities; Mental retardation; Paroxetine; Selective serotonin re uptake inhibitors; Side effects; Treatment emergent behaviour

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; AGGRESSION; AGITATION; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; HYPERACTIVITY; LEARNING DISORDER; MALADJUSTMENT; MALE; MOOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY;

EID: 0035076542     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.233     Document Type: Article

References (11)

1. Double blind study of the efficacy and safety of sertraline vs fluoxetine in major depression
2. Double-blind, fixed-dose, paroxetine in the treatment of panic disorder
3. Fluoxetine: Activating and sedating effects. Affective disorders: Current and future perspectives
4. A retrospective audit of selective serotonin re-uptake inhibitors (fluoxetine and paroxetine) for the treatment of depressive episodes in adults with learning disabilities
5. Selective serotonin re-uptake inhibitors in the treatment of affective disorders. III. Tolerability, safety and pharmacoeconomics
6. Comparative pharmacology of 5-HT re-uptake inhibitors
7. The comparative pharmacology of new antidepressants
8. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants
9. Sertraline 50 mg daily - The optimal daily dose in depression
10. Advances in the pharmacotherapy of depressive disorders